Namaste Technologies (CSE:N; OTCMKTS:NXTTF) announced the list of nominees for their 2018 board of director.

As quoted in the press release:


Namaste Technologies is pleased to announce that the Company has nominated Branden Spikes, Laurens Feenstra and Donald William Nickless (the “Nominees”) for positions on Namaste’s 2018 board of directors, in addition to current board members Sean Dollinger, Sefi Dollinger and Kiranjit Sidhu. These three new Nominees represent a major milestone for Namaste in solidifying the board and supporting the Company’s future growth within the cannabis industry. The Nominees and proposed board members have served in critical roles at Google, SpaceX and Seagram’s International, and bring an intangible amount of value in helping advance the Company’s technology through innovation.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; From the outset, Namaste has been focused on revolutionizing the cannabis industry through innovation.  These Nominees represent an incredible opportunity for Namaste to not only strengthen the team but to significantly broaden the scope of our vision to revolutionize the industry. The combined experience and knowledge these individuals possess cannot be measured and we feel extremely privileged to have them willing to join our team and contribute significantly to the future direction of Namaste. Our entire team remains focused in our efforts and is committed in helping to redefine the industry. We strongly believe these Nominees will help drive future growth opportunities and help solidify Namaste as a global leader in the development of cannabis technology solutions.”

Click here to read the full press release.

Source: marijuanaindex.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less